The effect on platelet aNivation of monoclonal antibodies directed against common determinants of the HLA class I heavy chain molecule was studied. Cross-linking W6/32, an anti-HLA class I of lgG2a subclass, led to platelet activation. Two other antibodies of the same subclass did not have this effect on platelets. The lack of activity of the F(ab'Iz frag. ments suggests that the activation signal is mediated by the platelet Fc receptor (FcyRII). Indeed, except for a higher sensitivity of W6/32 to aspirin and apyrase, activations by cross-linking IV-3 (an anti-FcyRII) and W6/32 are similar at LASS I MOLECULES of the human major histocom-C patibility complex (HLA) are membrane glycoproteins expressed on the surface of most cells. The complex is formed of two different chains, the 45-Kd transmembrane glycosylated chain bearing polymorphic determinants, noncovalently associated with the 12-Kd monomorphic, nonglycosylated, p2-microglobulin. HLA class I molecules appear to play an important role in immune functions, including restriction of cytotoxic functions' and presentation of antigenic peptides to cytotoxic T lymphocytes.2 Recently, HLA class I antigens were shown to transduce an activation signal in T lymphocytes, ie, calcium mobilization, on addition of specific monoclonal antibodies (MoAbs) and crosslinking by a second antibody anti specie^.^^ This effect is relevant for cell activation because it potentiates the proliferation of T cells induced by CD3 MoAbs.
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Platelets also express, according to different investigators 20,000 to 100,000 HLA class I molecules on their surface.7p8
The exact role of HLA class I complexes on platelets is still unknown. However, they may be involved in the development of platelet immune disorders such as autoimmune thrombocytopenia, posttransfusion purpura, systemic lupus erythematosus, or rheumatoid arthritis-associated platelet thrombocytopenia. Indeed, different investigators reported the presence of HLA class I autoantibodies in the plasma of patients suffering from such disea~es.~-l' Some of these antibodies have been shown to activate platelets in vitro and to interfere with adenosine diphosphate (ADP) or collagen activation?JO These effects led some investigators to suggest that HLA class I antigens may be important for platelet activation.
A recent report from Endresen12 presented evidence that HLA class I antibodies block the fixation of IgG Fc fragments on platelets. This suggested an interaction between the antibody, the HLA class I antigens, and the platelet Fc receptor (FcyRII). This receptor is a 40-Kd molecule that can bind specifically human and mouse IgG. It has been shown to transduce a signal leading to platelet activation, when cross-linked by immune complexes, aggregated IgG, or by a mouse MoAb (IV-3) specific for this receptor, plus a second antimurine antibody. [13] [14] [15] The Fc receptor is thought to be of importance during immune thrombocytopenic purpura (ITP) or posttransfusion purpura. Indeed, it was recently shown in an in vitro model that platelet-activating antibodies such as CD9 MoAbs or certain anti-GPIIb/IIIa MoAbs would activate platelets only if their Fc portion interacted with F c~R I I .~~-~~ It is hypothethe level of lnsP3 formation, calcium mobilization, pH modifications, and activation of protein kinase C and myosin kinase. When HLA class I molecules and FcyRll are crosslinked together, platelet activation occurs. This is not observed when a control lgG2a is substituted for W6/32 or when CD9 and Fc receptor are cross-linked together. This suggests that HLA class I molecules and FcyRll synergize to activate platelets. Q 1992 by The American Society of Hematology.
sized that in a second step these aqtibodies induce an oligomerization of the Fc receptor followed by platelet activation. Thus, the present study addresses the question whether the activation observed after cross-linking class I antigens was caused by specific properties of HLA class I antigens or to an activation through Fc receptor.
MATERIALS AND METHODS
Antibodies. Production and characterization of the CD9 MoAb SYB-1 (IgG1) aswell as the anti-FcyRII MoAb IV-3 (IgGZb), were described previo~sly.'~~2~-~~ The anti-HLA class I heavy chain (common determinant) MoAbs, all of the IgG2a subclass, were purchased from Accurate Chemicals and Scientific Corp (Westbury, NY) (W6/32), AMAC (IOT2 = clone B9.12.1) and Chemicon (Temecula, CA) (MoAb 1280). The polyclonal F(ab')z goat antimurine IgG [F(ab')z specific: GaM-F(ab')z] was obtained from Jackson Immuno Research Laboratories Inc (West Grove, PA).
For the preparation of F(ab')z fragments, W6132 was dialyzed against 100 mmol1L sodium citrate pH 3.5 before addition of pepsin agarose (Sigma, St Louis, MO) at 25% wtlwt. The reaction was allowed to proceed for 12 hours at 37°C and yielded F(ab')z fragments as analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Blood was collected from volunteers giving informed consent who denied taking any medication for the previous 2 weeks. The blood was drawn from the antecubital vein into syringes containing 0.1 volume of CCD (100 mmol1L sodium citrate and 130 mmol/L glucose, pH 6.5). The blood was centrifuged 3 minutes at 1 , q at room temperature to separate the platelet-rich plasma (PRP) that was cooled on ice for 15 minutes.
One-half volume of 4°C CCD buffer was added and the platelets were pelleted at 9OOg for 10 minutes at 4°C. The supernatant was decanted and the platelets resuspended in a modified Tangen-HEPES-BSA bufferz4 (pH 7.4) containing 145 mmol/L sodium chloride, 5 mmol/L potassium chloride, 0.1 mmol/L magnesium chloride, 0.05 mmol/L calcium chloride, 5.5 mmol/L glucose, 15 mmol/L HEPES, and 1 mg/mL bovine serum albumin (BSA). The platelet suspension was warmed to 37°C and then incubated with either 0.5 mCi/mL 32P-orthophosphate (Dupont/New England Nuclear Products [Dupont-NEN], Boston, MA) for 45 minutes or 0.05 pCi/mL 14C-serotonin (Amersham Corp, Arlington Heights, IL), 2 p,mol/L Fura-2 (Acetoxymethyl ester; Molecular Probes) or 10 pmol/L 2',7'-bis-(2-carboxyethyl)-5-(and 6) carboqdluorescein (BCECF, Acetoxymethyl ester; Molecular Probes) for 15 minutes. After chilling, the platelets were filtered on a Sepharose-2B column (Sigma) as previously described."
Aggregation of gel-filtered platelets (GFP) was determined at 37°C with constant stirring on a Payton dual channel aggregometer (Payton Scientific, Inc, Buffalo, NY) calibrated to 100% light transmittance with Tangen-HEPES-BSA. Percent aggregation was calculated by setting 100% light transmittance as equivalent to 100% aggregation and the transmittance through unstimulated GFP was equated to 0% aggregation.
Platelet immunofluorescence. Immunofluorescence analysis was performed using a 1024 channel Becton Dickinson (Mountain View, CA) FACStar Plus flow cytometer at 488 nm excitation. GFP were treated with 200 pmol/L aspirin, 0.1% sodium azide, and 1 pg/mL prostaglandin El (PGE1) to prevent activation. The binding of the different anti-HLA class I antibodies was determined by exposing the platelets to 10 p,g/mL of unlabeled antibody followed, after washing twice with RPMI 1640 (GIBCO BRL, Grand Island, NY), by fluorescein isothiocyanate (F1TC)-goat F(ab')z antimurine IgG (Boehringer Mannheim, Indianapolis, IN). All incubations were for 30 minutes at 4°C. The logarithmic mean fluorescence channel intensity (L) was converted to linear units (1) by the formula: 1 = GFP aliquots were monitored by aggregometry and triplicate 0.1" aliquots were taken after maximum aggregation was reached. These were immediately mixed with 0.9 mL of ice-cold phosphate-buffered saline (PBS) plus 10 mmol/L EGTA and 0.2% glutaraldehyde to stop release. The platelets were removed by centrifugation for 3 minutes at 10,OoOg before taking 0.5-mL aliquots of the supernatant for scintillation counting of released 14C-serotonin. Similarly diluted aliquots, which were not centrifuged, were counted for total label. Control counts per minute (cpm), which were less than 10% of the total cpm, were subtracted from both the sample cpm and total cpm. Percent release was calculated by dividing the corrected sample cpm by total cpm and multiplying by 100.
Aliquots were taken as described above except that they were diluted in 4°C PBS/EGTA buffer without glutaraldehyde. Supernatants were diluted 10 times in distilled water and then assayed with a commercial radioimmunoassay kit (Amersham) according to the manufacturer's instructions. Control levels of P-thromboglobulin were subtracted from samples and total values, determined on freeze-thaw-sonicated lysed platelets. Platelets were loaded as described above with the dyes Fura-2 and BCECF, specific for CaZ+ and H+, respectively. Fura-2 fluorescence emission at 510 nm was monitored with a Shimadzu RF-5000 fluorometer (Columbia, MD) in plastic cuvettes thermostated at 37"C, under constant stirring. Each point of the trace corresponds to the ratio of the emission fluorescence obtained with excitations at 335 and 360 nm (isobestic point). BCECF fluorescence was monitored for emission at 530 nm with 495 nm excitation. GFP at 5 X 108/mLwere activated by cross-linking W6/32 or IV-3 under constant stirring. 300 pL aliquots were taken at indicated times, mixed with 60 pL of 100% ice-cold trichloroacetic acid, and incubated in ice for 15 minutes. Samples were then centrifuged for 2 minutes at 10,OoOg and the supernatants were collected and incubated at room temperature for 15 minutes. Six hundred microlitres of a 3: 1 solution of 1,1,2-trichloro-1,2,2-trifluoroethane (TCTFE)/trioctylamine was then added to remove trichloroacetic acid. The tubes were thoroughly vortexed, incubated for 3 minutes at room temperature, and the upper aqueous phase was carefully sampled. The quantification of InsP3 present in the samples was performed using a Dupont-NEN radioimmunoassay, according to the manufacturer's instructions.
Platelets were labeled with 32P-orthophosphate as described above. After addition of agonist, platelet aliquots (50 pL) were taken at indicated times, immediately mixed with 30 pL of reducing denaturation buffer (6% SDS, 6% p-mercaptoethanol, 15 mmol/L EGTA, 30% glycerol, 0.03% bromophenol blue, 150 mmol/L Tris-HC1, pH 6.8), electrophoresed and autoradiographed to visualize 32P-labeled peptides, as previously described. 25 Label associated with the 20-Kd myosin light chain (p20) and a 47-Kd cytosolic phosphoprotein of unknown function (p47) was quantified by a Zeineh Laser Densitometer (Biomed Instruments Inc, Chicago, IL) with adjustable slit width set to cover the entire width of the gel lane. The peak area associated with the p20 or p47 bands was quantified on an interfaced Shimadzu CR3-A recording integrator.
Platelets were labeled with 32P-orthophosphate as described above. Control, PMA, or W6/32 activated samples were lysed in equal volumes of 2X extraction buffer (2% Triton X-100, 100 mmol/L Tris-HC1, 20 mmol/L P-glycerophosphate, 4 mmol/L molybdic acid, 10 mmol/L EGTA, and 2 mmol/L P-mercaptoethanol). After addition of 1 mmol/L MgC12, 0.5 mol/L NaCl and 2.5 mmol/L adenosine triphosphate (ATP), the lysates were sonicated to dissolve the platelet cytoskeleton. Immunoprecipitation was performed by adding 10 pg/mL of antibodies and, after 30 minutes incubation at 4"C, 20 pL of protein G-sepharose (Pharmacia LKB Biotechnology, Piscataway, NJ). After a 2-hour incubation at 4"C, the beads were pelleted, washed three times in extraction buffer, and resuspended in 70 pL of reducing denaturation buffer before electrophoresis.
Phosphorylation of myosin light chain and p47. the IgG2a subclass) were tested for their ability to activate platelets separated from plasma. Activation was determined by the measure of serotonin released from the dense granules to the buffer ( Table 1) . None of these antibodies activated platelets. Nevertheless, W6/32 induced serotonin release after cross-linking with 60 p,g/mL of the F(ab')2 fragments of a goat antimurine polyclonal antibody [F(ab')z fragment specific, GaM-F(ab')z]. The maximum serotonin secretion was observed with 8 pg/mL of W6/32,59% rf: 5% of total platelet serotonin content, and was significantly less than maximum secretion obtained with IV-3 (77% rf: 2%) cross-linked by GaM-F(ab')2. The F(ab')z fragments of this second antibody were used through this study to avoid nonspecific Fc receptor activation by immune complexes. The fact that among these antibodies, only one activates with a cross-linking antibody indicates that this phenomenon is not caused by nonspecific activation through FcyRII by IgG "aggregated" by the cross-linking antibody. tW-serotonin labeled platelets were treated with increasing concentrations of different anti-HLA class I MoAbs (up to 20 pg/mL), with or without cross-linking GaM-F(ab'), (60 FglmL), and the release of serotonin was measured and expressed as a percentage of total serotonin granule content. The table only shows secretion induced by the concentration of W6/32 antibody giving maximum effect (8 p/ mL).
Immunoprecipitation.

RESULTS
Differential
Platelets were then incubated at 4°C with saturating amount of MoAbs, followed by a second incubation with a FITC-goat antimurine (FITC-GaM) IgG, and then analyzed by flow-cytofluorometry (Table l) . The absence of activation with MoAb 1280 could be related to the smaller intensity of cell staining. The fact that IOT2 and W6/32 MoAbs stained the platelets with similar intensity suggests that platelet activation by anti-HLA class I antibodies depends on the epitope recognized by these antibodies.
Platelet aggregation induced by cross-linking W6/32. The mechanism by which W6/32 activated GFP was further investigated. A lag-time preceding aggregation was observed with both W6/32 and IV-3. Pretreatment of platelets with PGE1, a platelet inhibitor that increases the activity of adenylate cyclase and, therefore, raises the intracellular level of cyclic AMP (adenosine 3'3' cyclic monophosphate) prevented aggregation and serotonin release induced by this antibody (data not shown). Thus, this represents true platelet aggregation and not antibody-mediated agglutination. Platelets were also pretreated with aspirin to inhibit the formation of thromboxane A2. This treatment did not modify the lag-time following cross-linking HLA class I molecules (Fig 1) but reduced its aggregation from 78% rf: 6% to 55% f 11% (30% f 12% inhibition) and that following FcyRII cross-linking from 80% +. 6% to 70% f 6% (14% rf: 5% inhibition).
Differential regulation of (Y and dense granule secretion.
Measurements of serotonin and p thromboglobulin were performed as markers of secretion of dense and (Y granules, respectively. After cross-linking, W6/32 induced similar releases of serotonin and p thromboglobulin, 59% f 5% and 63% rf: 12% of total granule content respectively. Aspirin pretreatment differentially reduced dense and (Y granule secretion by 85% f 6% and 26% rf: 18% respectively (Fig 2) . This differential sensitivity is similar for the activation by cross-linking IV-3 (77% rf: 12% inhibition of serotonin secretion and 35% f 18% inhibition of p thromboglobulin secretion).
Fc receptor-mediated platelet activation has been previously reported to trigger a strong Calcium mobilization. Thromboxane A2 is known to induce calcium mobilization by activation of phospholipase CZ7 and by direct effect on internal storage ~0 0 1 .~ To investigate the role of this second messenger in the activation by W6/32 and IV-3, platelets were pretreated with aspirin five minutes before addition of antibodies (Fig 3, trace b) . This treatment had some inhibitory effect on calcium mobilization by both antibodies but was unable to block it completely.
To investigate the role of extracellular calcium, GFP were treated with both EGTA and aspirin before addition of antibodies (Fig 3, trace c) . The peak of calcium flux following W6/32 or IV-3 plus cross-linking antibody was only slightly reduced by this treatment. A striking modification of the trace was that it returned to basal level after a few minutes, suggesting that entrance of extracellular calcium was responsible for the persistent [Ca2+]i elevation.
It has also been suggested that ADP directly provokes calcium mobilization from internal stores.29 Platelets were treated by the ADP scavenger apyrase in addition to aspirin and EGTA (Fig 3, trace d) . This pretreatment strongly reduced calcium mobilization induced by cross-linking W6/32 or IV-3, but, again, failed to completely inhibit it.
Production of D-myo-inositol I-, 4-, 5-triphosphate. Because the [Ca2+]i increase observed during platelet activation is partially independent of ADP and thromboxane A2, we hypothesized that it was mediated by the phospholipase C-dependant formation of InsP3. Basal levels of InsP3 were found to be 0.5 to 1 nmol/108 platelets. Both W6/32 and IV-3 induced after cross-linking a twofold to threefold increase of InsP3, mostly independent of the cyclooxygenase pathway (Fig 4) . In aspirin treated platelets, production of InsP3 after W6/32 plus GaM-F(ab')2 activation was strongly dependent on the amplification by secreted ADP. A slow increase of total InsP3 was then observed (1.5-fold increase), contrasting with the rapid peak of calcium mobilization occurring under the same conditions.
Platelet activation by different agonists, including Fc receptor specific activators, is thought to be mediated by aspirin sensitive and insensitive pathways. This insensitive pathway would involve phospholipase C activation and activation of Na+/H+ exchange pump resulting in cytoplasmic alkalinization.26 To study this parameter, platelets were loaded with the fluorescent dye BCECF. The addition of either IV-3 or W6/32, plus a second antibody, induced a similar increase of fluorescence that was not blocked by aspirin plus apyrase (Fig 5) .
Platelet proteins phosphorylation. The phosphorylation of several platelet proteins has been reported to be important for granule secretion.3O Thus, the differential effect of aspirin on (Y and dense granules led us to investigate the phosphorylation of myosin light chain (p20), and p47, the Cytoplasmic alkalinization. Because phosphorylation is important for the regulation of the activity of different molecules, the possible phosphorylation of several proteins during activation by W6/32 or IV-3 plus cross-linking antibody was studied using immunoprecipitation techniques. These molecules were HLA class I, FcyRII, and CD9 antigen. CD9 antigen was studied, because of its special relationship with FcyRII.16 As previously HLA class I heavy chains were shown to be phosphorylated in resting platelets (Fig 7, lanes 3,4, and  8 ). An increase of the phosphorylation of this molecule was observed 5 minutes after platelet activation by PMA32 (lane 6). No effect was detected 2 minutes after activation (lane 5). By contrast, cross-linking of platelet HLA class I molecules did not modify the phosphorylation of this molecule during the first 5 minutes (lanes 7 and 9 through 12). Because maximum secretion and aggregation are reached in 5 minutes, later modifications of phosphorylation would not be relevant for platelet activation.
Neither CD9 antigen or FcyRII incorporated 32P-label, before (Fig 7, lanes 1 and 2) or after activation by a CD9 MoAb SYB-1, or cross-linking of Fc receptor or HLA class I molecules (data not shown).
To investigate the possibility of an Fc receptor-mediated activation, F(ab')z fragments of W6/32 were made. Platelets incubated with these fragments and cross-linked by GaM-F(ab')z did not activate (Table 2) . This was not caused by an inefficient binding of these fragments to the platelet HLA class I antigens as monitored by indirect immunofluorescence (data not shown). Preincubation of platelets with these fragments inhibited the activation obtained with the corresponding whole antibody (data not shown).
The anti-FcyRII, IV-3, directed against the Fc binding site, has been a useful tool to demonstrate the role of this receptor in antiplatelet MoAb-induced platelet activation. Because IV-3 activates platelets when cross-linked by GaM-F(ab')2,l3J4 we had to modify the approach to investigate the role of FcyRII for W6/32-induced platelet activation. High concentrations of IV-3 (32 pg/mL) proved unable to activate platelets after addition of the crosslinking antibody. However (Table 2) , platelets became activated when treated with such concentrations of IV-3 (32 Fg/mL), W6/32 (8 pg/mL), and the cross-linking antibody (60 Fg/mL). Furthermore, platelet pretreated with both IV-3 at this same concentration, and W6/32 F(ab')z (5 FgImL), became activated when GaM-F(ab')z was added. This activation was accompanied by calcium mobilization from an internal storage pool and pH alkalinization (data not shown). We next performed controls to rule out the hypothesis that the addition of W6/32 or W6/32 F(ab')2 to IV-3 pretreated platelets (at 32 Fg/mL) would restore conditions allowing efficient cross-linking of FcyRII. Substituting either an irrelevant IgG2a or IOT2 for W6/32 failed to activate platelets when GaM-F(ab')2 was added in the presence of IV-3 at this concentration. Other controls were run with SYB-1, a CD9 MoAb that activates platelets through the Fc receptor. It has been shown that after binding on CD9 antigen, the Fc domain of this antibody interacts with FcyRII to trigger activation.16 Because we Synergy between FcyRII and HLA class I molecules. (1) SYB-1, (2)  IV-3, or (3 to 12) know that CD9 antigen and FcyRII are able to interact, addition of GaM-F(ab')z to SYB-1 and IV-3 is likely to cross-link CD9 antigen and FcyRII together. No activation could be observed when SYB-1 or its F(ab')2 fragments were used instead of W6/32. These data suggest that platelet activation observed in the presence of high concentrations of IV-3 and W6/32 is specific for this antibody.
cules, induces platelet activation. This activation was not observed when the F(ab'h fragments of this antibody were used, suggesting that cross-linking HLA class I antigens by itself is not sufficient to trigger activation. This is in accordance with the fact that only one out of three antibodies was able to activate platelets after cross-linking. Thus, the mechanisms by which cross-linking HLA class I antigens induce cell activation are likely to be different in platelets and in T cells."
The biochemical events of platelet activation by crosslinking anti-HLA class I MoAbs were studied in comparison with the activation produced by cross-linking the platelet Fc receptor. Cross-linking HLA class I molecules by W6/32 induces an elevation of [Ca2+]i resulting from both mobilization from internal storage pool and entrance of external calcium. A combination of apyrase and aspirin failed to completely inhibit this calcium mobilization, suggesting that ADP secretion and thromboxane A2 formation are not entirely responsible for this mobilization. In fact, beside ADP38 and thromboxane A2," a variety of activators, including thrombinP9 platelet activating factor?9 and collagen,40 have been shown to directly activate phospholipase C thereby inducing the formation of diacylglycerol, a potent activator of protein kinase C, and InsP3, which can mobilize calcium from internal reservoirs. Here we show that the cross-1inking Of w6/32 leads to the formation Of InsP3 which is likely to be mediated by activation of phospholipase C. This formation is almost entirely independent of thromboxane A2 formation and is only partially inhibited when preventing amplification by both ADP secretion and thromboxane A2 production. Thus, the activa-
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<1 ND tion observed after cross-linking W6/32 on platelet surface is likely to be directly coupled to phospholipase C. dent on ADP secretion and thromboxane A2 formation.
Other similarities between the activation caused by W6/32 and IV-3 include activation of protein kinase C and myosin gested bY siffert and Akkerman$1 this a1ka1inization is likely to result from amplification of Na+/H+ pump activity by protein kinase C.
DISCUSSION
Recent studies have shown that cross-linking of HLA class I antigens on the surface of T lymphocytes triggers an elevation of [Ca2+]i and costimulates proliferation induced by other activators such as CD3 MoAbs or PMA.36 Because this effect is observed after deletion of the cytoplasmic tail of HLA class I33 molecules, it was suggested that crosslinking may induce the association with another surface molecule that transmits an activation signal. Although HLA class I molecules have been shown to be associated with different receptors, such as epidermal growth factor, interleukin-2, or insulin receptors on different cell ~ystems,3~3~ no data are available on the ability of HLA class I molecules to deliver an activation signal to these cells. The present study shows that cross-linking of W6/32, a MoAb directed against a monomorphic determinant of HLA class I mole- Although W6/32 induced activation proved to be more sensitive to the amplification by thromboxane A2 and ADP than IV-3, aspirin dramatically reduced serotonin secretion in both systems but had only little effect on the secretion of P-thromboglobulin. This result confirms the hypothesis by Krishnamurthi et a142 that there are differences in the mechanisms for release of dense and a. granules.
FcyRII has recently been shown to play a central role in platelet activation by other monoclonal antibodies. The lack of activity of the F(ab')z fragments of W6/32 indicated that the Fc domain was necessary, presumably, to cross-link HLA class I antigens and FcyRII together. The similarity of the signal transduction to the direct cross-linking of IV-3 by GaM-F(ab')p suggested that FcyRII oligomerization or immobilization conveys the signal, However, this report presents evidence that cross-linking of HLA class I molecules together with FcyRII synergistically induces platelet activation. High concentrations of IV-3 fail to activate platelets after addition of second antibody, probably because of insufficient cross-linking of the receptor. Addition of W6/32 and IV-3 before addition of second antibody, to cross-link HLA class I antigens to FcyRII, induced platelet activation. In fact, under these conditions, W6/32 could be replaced by its F(ab')2 fragments and still trigger platelet activation. By contrast, when SYB-1, a CD9 MoAb that activates platelets through FcyRII, or its F(ab')* fragments were added under the same conditions to cross-link CD9 antigen with FcyRII, no activation could be obtained. Similarly, no activation occurred when another anti-HLA class I, IOT2, or an irrelevant antibody were used instead of W6/32. Together, these data suggest that it is the crosslinking of FdyRII to HLA class I molecules that induces platelet activation. This is the most likely explanation because cross-linking of HLA class I antigens by W6/32 F(ab')* fragments does not lead to platelet activation, and under these conditions of excess IV-3 MoAb, the second antibody is saturated and is unable to cross-link the Fc receptor efficiently. Moreover, the number of HLA molecules being much greater than FcyRII, the IV-3 MoAbs, if randomly distributed, are more likely to be cross-linked to W6/32 than to other IV-3 MoAbs. Additionally, this synergistic effect is specific for HLA class I molecules because Fc receptor failed to activate platelets when cross-linked to CD9 antigen. The ability of HLA class I molecules to synergize with FcyRII is further supported by the fact that W6/32 is of the IgG2a subclass. Antibodies of this subclass have previously been reported to have low affinity for F c~R I I .~~ Indeed, in a survey of the recent literature, we found 24 platelet-activating MoAbs directed against different antigens. Twenty-two of them, including one directed against p2 microglobulin,20 are of the IgGl subclass. Finally, these data suggest that HLA class I antigens must be in a specific conformation to synergize with Fc receptor, because another anti-HLA class I, IOT2 (B9.12.1), failed to activate platelets under the same conditions, despite an equal binding. W6/32 and IOT2 recognize different epitopes because they don't compete for binding.@ Interaction between different platelet antigens and FcyRII on the addition of antibodies specific for these antigens has been previously reported.16-20 These antibodies could induce platelet activation by oligomerization of Fc receptor present either on the surface of the same platelet or another platelet. They may represent a possible model for platelet destruction in immune thrombocytopenia. The present study shows the possibility of another interaction between a surface antigen and the Fc receptor that leads to synergistic activation of platelets. The physiopathologic consequences of this synergistic activation between HLA class I molecules and FcyRII are not clear. It is possible that HLA class I molecules bind bacterial or viral products. In this regard, it has been shown that cytomegalovirus expresses a molecule related to HLA class I antigen that can bind P2-mi~roglobulin.~~ It was proposed that cytomegalovirus binds to cell surface by deplacing the cellular @2-mi~roglobulin.~~ This led Geppert et a14 to suggest that T-cell polyclonal activation could occur after binding of cytomegalovirus to cellular P2-microglobulin, and subsequent cross-linking of HLA class I molecules. By a similar mechanism, cytomegalovirus or antibody-coated cytomegalovirus, may trigger platelet activation. This may be a relevant mechanism of platelet destruction in acquired immunodeficiency syndrome (AIDS), where cytomegalovirus infections are frequent.47.48
